Laparotomy Sponges Market size is likely to expand at a promising rate during the forecast period of 2023-2032 as laparotomy surgeries offer a wide range of advantages, such as safety, reliability, and ease of performance. The incidence of colonic volvulus and other gastrointestinal disorders is also rising among adults. Every year, 62 million individuals in the U.S. are diagnosed with a digestive or gastrointestinal disease. This scenario will boost the need for surgery and in turn, improve the adoption of laparotomy sponges.
The global prevalence of abdominal disorders, such as colon cancer and appendicitis, will bolster laparotomy sponges market gains during the analysis timeframe. According to the American Cancer Society, in 2022, the U.S. was estimated to record 106,180 new cases of colorectal cancer. This factor is predicted to stimulate the usage of sterile laparotomy sponges to remove colon tumors.
However, high preference for non-invasive surgeries and growing awareness of the benefits of alternative surgical procedures, such as reduced pain and faster recovery, may hamper the industry forecast.
Based on end-use, laparotomy sponges market is segmented into hospitals, surgical centers, and others. The surgical center segment will account for a large industry outlook by 2032. One of the key factors fueling the preference for these centers is the rising inclination towards outpatient surgical procedures to treat digestive disorders, such as hemorrhoids, which affects millions of Americans every year. Nearly 10.4 million people in the U.S. suffer from hemorrhoids, with 1 million new cases being recorded each year. This trend can increase the usage of laparotomy sponges, thereby stimulating the industry progress.
Based on product, laparotomy sponges market is bifurcated into sterile and non-sterile sponges. The market revenue from the sterile laparotomy sponge segment is set to grow exponentially during the analysis timeframe. Sterile sponges, which are generally used to treat highly exudative and dirty wounds, possess superior absorption properties, and offer great comfort to patients. These sponges also prevent the risk of cross contamination and can effectively control excessive bleeding. Such benefits will accelerate the market development.
Moreover, the number of women being diagnosed with ovarian cancer in the country is witnessing a steady hike. According to the European Society for Medical Oncology (ESMO), in 2022, 26,500 women were predicted to die from ovarian cancer in the EU. This will also propel the adoption of surgical lap sponges, as exploratory laparotomy surgery is recommended for treating this form of cancer.
Organizations, such as B. Braun Melsungen AG, Integra LifeSciences Holdings Corporation, Patterson Companies, DeRoyal Industries, Kendall Healthcare, DUKAL Corporation, Haldor Advanced Technologies, Dynarex, McKesson Medical-Surgical Inc., Medical Action Industries Inc. (Owens & Minor), Medtronic, Allcare Inc., Stryker, Texpol, AdvaCare Pharma, Derma Sciences Inc. (Integra LifeSciences), Jorgensen Laboratories Inc., and Cardinal Health, among others, are the leading players in laparotomy sponges market.